ArticleCureus2025
A Retrospective Study for the Evaluation of Serum Anti-Müllerian Hormone and Its Correlation With Insulin Resistance and Lipid Profile in Polycystic Ovary Syndrome in Adolescents.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and rationale Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder in adolescents, marked by hormonal imbalances, insulin resistance, and metabolic dysfunction. Early identification of reliable biochemical markers is crucial for timely diagnosis and management to prevent long-term complications like type 2 diabetes and cardiovascular disease. This study investigates serum anti-Müllerian hormone (AMH) and its correlation with insulin resistance and lipid profiles to identify predictive markers for PCOS risk in adolescents. Methods A retrospective study analyzed 91 women (49 PCOS cases per Rotterdam criteria, 42 age-matched controls; mean age 25.5 ± 5.3 years). Biochemical parameters, including AMH, insulin, fasting blood sugar (FBS), luteinizing hormone (LH), interleukin-6 (IL-6), lipid profiles (total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides (TG)), and electrolytes (sodium, chloride), were measured using standardized protocols on the Beckman Coulter AU series autoanalyzer. Insulin resistance was assessed via Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) and Quantitative Insulin Sensitivity Check Index (QUICKI). Statistical analyses included t-tests, logistic regression, exploratory factor analysis (EFA), and heatmap visualization of PCOS phenotypes (Groups A-D, based on clinical/biochemical severity). Results The PCOS group showed significantly higher insulin (mean difference: 5.2 µIU/mL, p = 0.003), HOMA-IR (p = 0.004), LH (p = 0.002), AMH (p < 0.001), and chloride (p < 0.001), with lower Na:Cl ratio (p < 0.001) and QUICKI (p = 0.005) compared to controls. Logistic regression identified AMH (odds ratio (OR): 1.45, p < 0.001), FBS (OR: 1.12, p = 0.02), and LH (OR: 1.33, p = 0.01) as key predictors. Model 5 (AMH, FBS, IL-6, LH) achieved a McFadden R² of 0.85 and area under the curve (AUC) of 1.00. EFA revealed five factors (36.4% variance): insulin resistance, liver/lipid function, lipid metabolism, liver/kidney function, and electrolyte/protein balance, all correlated with PCOS (p < 0.05). Heatmap analysis showed severe insulin resistance in Group D and elevated FBS/chloride in Group C. Conclusion AMH, LH, and FBS are robust markers for diagnosing and managing PCOS in adolescents. These, alongside insulin resistance and lipid alterations, support early risk stratification and personalized interventions across PCOS phenotypes, improving long-term health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.